8-K: Athira Pharma Stockholders Approve Reverse Split, Elect Directors at Annual Meeting

Athira Pharma, Inc. announced that its stockholders approved a reverse stock split and elected three Class II directors at its 2025 Annual Meeting, alongside ratifying Ernst & Young LLP as its independent auditor.

Summary

• Athira Pharma, Inc. held its 2025 Annual Meeting of Stockholders on May 29, 2025, with 71.58% of eligible shares (27,948,849 out of 39,042,445) present or represented.
• Stockholders elected Joseph Edelman, John M. Fluke, Jr., and Grant Pickering as Class II directors to serve until the 2028 annual meeting.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 26,981,568 votes For.
• Stockholders approved proposed amendments to the company's certificate of incorporation to effect a reverse stock split and reduce the total number of authorized shares of common stock.
• The reverse stock split can be at a ratio of 5-for-1, 10-for-1, 15-for-1, or 20-for-1, with the final ratio to be determined by the Board of Directors.

Sentiment

Score: 4

Explanation: The approval of a reverse stock split, while a necessary step for compliance, generally reflects a negative trend in the company's stock performance. While it provides a mechanism for potential recovery and future financing, it signals underlying challenges rather than strong positive momentum.

Positives

• Stockholders demonstrated engagement with a 71.58% turnout at the Annual Meeting.
• The election of all nominated directors and the ratification of the independent auditor provide stability in corporate governance and financial oversight.
• Approval of the reverse stock split provides the Board with a mechanism to potentially increase the per-share trading price, which could help meet Nasdaq listing requirements and attract a broader investor base.

Negatives

• The need for a reverse stock split typically indicates a low share price, which can be a negative signal regarding the company's market valuation and performance.
• A reverse stock split can sometimes lead to decreased liquidity and may not always result in a sustained increase in share price.

Risks

• The primary risk is the potential for the reverse stock split not to achieve its intended effect of increasing the stock price sufficiently or sustainably, potentially leading to continued low valuation or delisting concerns.
• Investor perception: Reverse stock splits can sometimes be viewed negatively by investors, potentially leading to further selling pressure.
• While the immediate effect of a reverse split is a reduction in outstanding shares, the underlying low stock price often precedes future capital raises that could be dilutive to existing shareholders.

Future Outlook

The approval of the reverse stock split provides Athira Pharma with the flexibility to adjust its share structure, which could be a strategic move to maintain Nasdaq listing compliance and potentially improve its stock's marketability. The specific ratio of the split will be determined by the Board at a later date.

Management Comments

• Mark Litton, President and Chief Executive Officer, signed the report on behalf of Athira Pharma, Inc.

Industry Context

Reverse stock splits are a common corporate action, particularly in the biotechnology and pharmaceutical sectors, where companies often have volatile stock prices and may trade at lower valuations during clinical development phases. Such actions are frequently undertaken to meet minimum bid price requirements for stock exchanges like Nasdaq, avoid delisting, and make shares more attractive to institutional investors who may have policies against investing in 'penny stocks'.

Comparison to Industry Standards

• The approval of a reverse stock split is a common strategy employed by small-cap biotechnology companies, such as Athira Pharma, when their stock price falls below exchange minimums (e.g., Nasdaq's $1.00 bid price requirement). Companies like Sorrento Therapeutics (SRNE) and Athersys (ATHX) have also executed reverse stock splits to maintain listing compliance.
• The election of directors and ratification of auditors are standard annual meeting procedures, aligning with typical corporate governance practices across the industry.

Corporate Governance

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, with a proportional increase in the per-share price, though the total value of their holdings should remain unchanged immediately after the split.
• The reverse split aims to maintain Nasdaq listing, which benefits shareholders by ensuring continued market access and liquidity.

Next Steps

• The Board of Directors (or a duly authorized committee) will determine the final ratio for the reverse stock split (5-for-1, 10-for-1, 15-for-1, or 20-for-1) in its sole discretion.
• Implementation of the approved amendments to the company's amended and restated certificate of incorporation to effect the reverse stock split and reduce authorized shares.

Key Dates

Keywords

Athira Pharma, ATHA, SEC Filing, 8-K, Annual Meeting, Stockholders Meeting, Reverse Stock Split, Corporate Governance, Director Election, Auditor Ratification, Biotechnology, Pharmaceuticals, Nasdaq Compliance